Form 4 for MNPR Monopar Therapeutics
Accepted 2023-01-03 00:00:00 ET · period of report 2022-12-31 · accession 0001437749-23-000160 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Robinson Chandler | CEO, Dir | M - OptEx | — | +20.6K | 77.1K | +37% | — |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Robinson Chandler | CEO, Dir | F - Tax | $2.37 | -7,141 | 72.3K | -9% | -$16.9K |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Robinson Chandler | CEO, Dir | M - OptEx | $0.00 | -20.6K | 6,724 | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-01 | M | A | 6,723 | — | 79,056.80 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 2 | Common | Common Stock | 2023-01-01 | F | D | 2,327 | $2.37 | 76,729.80 | D | — | — | |
| 3 | Common | Common Stock | 2022-12-31 | F | D | 4,814 | $2.37 | 72,333.80 | D | — | — | |
| 4 | Common | Common Stock | 2022-12-31 | M | A | 13,912 | — | 77,147.80 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 5 | Derivative | Restricted Stock Units | 2022-12-31 | M | D | 13,912 | $0.00 | 151,171 | D | — · — to — | 13,912 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. (F5) On February 2, 2022, the reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
| 6 | Derivative | Restricted Stock Units | 2023-01-01 | M | D | 6,723 | $0.00 | 6,724 | D | — · — to — | 6,723 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F6) On January 31, 2020, the reporting person was granted 26,895 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |